MORGAN STANLEY PLC/CALL/MERCK & CO./135/0.1/21.03.25 Stock

Warrant

DE000MB745M9

Real-time Bid/Ask 11:05:45 2024-07-05 am EDT
0.61 EUR / 0.62 EUR +9.82% Intraday chart for MORGAN STANLEY PLC/CALL/MERCK & CO./135/0.1/21.03.25
Current month-25.33%
1 month-26.32%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-05 0.59 +5.36%
24-07-04 0.56 -6.67%
24-07-03 0.6 -13.04%
24-07-02 0.69 -4.17%
24-07-01 0.72 -4.00%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 09:11 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying MERCK & CO., INC.
Issuer Morgan Stanley
WKN MB745M
ISINDE000MB745M9
Date issued 2023-06-07
Strike 135 $
Maturity 2025-03-21 (259 Days)
Parity 10 : 1
Emission price 0.78
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.09
Lowest since issue 0.143
Spread 0.01
Spread %1.61%

Company Profile

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
-
More about the company

Ratings for Merck & Co., Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Merck & Co., Inc.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
125.8 USD
Average target price
142.7 USD
Spread / Average Target
+13.37%
Consensus